Acute blood pressure reduction exceeding safety and autoregulatory limits following rapid-acting antihypertensives for hypertensive urgency

View at publisher Summarise with VIRAT
Authors: Richard Alfred Preston, Evelyn V. Caizapanta, David R. Afshartous, Langely Chaparro, Pamella A.M. Bueno, Gisselle Jimenez, Phillip Rubin, Jeffrey N. Bernstein
Cited by: 0
References: 43

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Severe hypertension without associated hypertensive target organ injury is termed hypertensive urgency. Treatment guidelines for the initial 4-6 hours uniformly warn against extreme (e.g. >80 mmHg) reduction in SBP and reduction more than 25% below baseline mean arterial pressure (MAP), the approximate lower limit of cerebral autoregulation. We hypothesized that rapid-acting antihypertensive regimens commonly employed for hypertensive urgency can reduce SBP and MAP in excess of these limits, potentially compromising cerebral blood flow. METHODS: Retrospective cohort study in 1553 patients with hypertensive urgency to assess 5-hour SBP and MAP responses to the most commonly administered single-drug regimens ( n = 453), combined single-drug and multiple-drug regimens ( n = 1051), and no drug ( n = 199). Co-primary endpoints: number (%) SBP reduction greater than 80 mmHg and number (%) MAP reduction more than 25%. RESULTS SINGLEDOSE: rapid-acting oral clonidine ( n = 214), intravenous hydralazine ( n = 93), and intravenous labetalol ( n = 40), produced 5-hour SBP reduction of more than 80 mmHg in 38/214 (18%), 17/93 (18%), and 8/40 (20%) patients, respectively, and MAP reduction of more than 25% in 98/214 (46%), 41/93 (44%), and 15/40 (38%) patients, respectively. Conversely, oral extended-release nifedipine ( n = 84) and oral lisinopril ( n = 22) produced SBP reduction of more than 80 mmHg in 1/84 (1%) and 1/22 (5%) patients. MAP reductions of more than 25% were also fewer: 18/84 (21%) and 2/22 (9%) patients.Combined single-drug/multidrug combinations ( n = 1051) and no drug ( n = 199) demonstrated similar excessive SBP and MAP reductions. DISCUSSION: Our results demonstrate frequent extreme SBP and MAP reductions exceeding safety and autoregulatory limits with rapid-acting antihypertensives and the crucial need to develop and test novel clinical algorithms for the well tolerated and effective management of hypertensive urgency.

Fields of Study & Subjects

Blood Pressure and Hypertension Studies Acute Ischemic Stroke Management Hemodynamic Monitoring and Therapy

Publication details

Journal / source
Journal of Hypertension
Volume
44
Issue
7
Pages
1137–1148
Publication date
13 May 2026
Language
EN